CR9828A - Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa - Google Patents

Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa

Info

Publication number
CR9828A
CR9828A CR9828A CR9828A CR9828A CR 9828 A CR9828 A CR 9828A CR 9828 A CR9828 A CR 9828A CR 9828 A CR9828 A CR 9828A CR 9828 A CR9828 A CR 9828A
Authority
CR
Costa Rica
Prior art keywords
inhibitor
new mode
cyclooxygenase enzyme
modified
cyclooxygenase
Prior art date
Application number
CR9828A
Other languages
English (en)
Inventor
Jain Rajesh
Chand Jindal Kour
Singh Sukhjeet
Talwar Munish
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CR9828A publication Critical patent/CR9828A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee una presentacion farmaceutica de liberacion modificada que comprende al menos un inhibidor de la enzima ciclooxigenasa o sus sales, esteres, profarmacos, solvatos, hidratos o derivados farmaceuticamente aceptables como agente activo, con un portador farmceuticamente aceptable para controlar la liberacion del inhibidor de enzima ciclooxigenasa.
CR9828A 2005-07-20 2008-03-26 Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa CR9828A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1899DE2005 2005-07-20

Publications (1)

Publication Number Publication Date
CR9828A true CR9828A (es) 2008-07-31

Family

ID=37669241

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9828A CR9828A (es) 2005-07-20 2008-03-26 Nueva forma de dosificacion farmaceutica de liberacion modificada para un inhibidor de la enzima ciclooxigenasa

Country Status (20)

Country Link
US (1) US20100204333A1 (es)
EP (1) EP1906933A2 (es)
JP (1) JP2009501785A (es)
KR (1) KR20080032209A (es)
CN (1) CN101227893A (es)
AR (1) AR055090A1 (es)
AU (1) AU2006271150A1 (es)
BR (1) BRPI0613547A2 (es)
CA (1) CA2614850A1 (es)
CR (1) CR9828A (es)
DE (1) DE202006020331U1 (es)
DK (1) DK200900115U1 (es)
EA (1) EA200800370A1 (es)
MX (1) MX2008000967A (es)
NO (1) NO20080697L (es)
RS (1) RS20080020A (es)
TN (1) TNSN08018A1 (es)
UA (1) UA89684C2 (es)
WO (1) WO2007010559A2 (es)
ZA (1) ZA200801592B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101431992A (zh) * 2006-04-24 2009-05-13 万能药生物有限公司 包含尼美舒利的新型低剂量药物组合物及其制备和用途
JP5432716B2 (ja) 2006-10-17 2014-03-05 ヌーボ リサーチ インコーポレイテッド ジクロフェナクゲル
US8546450B1 (en) * 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
CN102188386B (zh) * 2010-03-02 2013-09-04 海南葫芦娃制药有限公司 尼美舒利缓释微丸及其制备方法
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2015503583A (ja) * 2012-01-04 2015-02-02 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための延長放出製剤およびその使用の方法
CN104144606B (zh) 2012-02-06 2016-11-16 创新医学概念有限责任公司 包含泛昔洛韦和塞来考昔的药物组合在制备治疗易感或患有功能性躯体综合征的受试者的药物中的用途
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
JP2019031556A (ja) * 2018-10-31 2019-02-28 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
ES2129010B1 (es) * 1997-01-02 2000-01-16 Gold Oscar Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion.
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
IN188720B (es) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
AU718356B2 (en) * 1998-01-12 2000-04-13 Panacea Biotec Limited A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs
WO2000004879A1 (en) * 1998-07-24 2000-02-03 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
US6086920A (en) 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
ATE232382T1 (de) 1998-09-10 2003-02-15 Nycomed Danmark As Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
AP1954A (en) * 1999-09-28 2009-02-10 Panacea Biotec Ltd Controlled release compositions comprising nimesulide.
IN190018B (es) * 1999-09-28 2003-05-31 Panacea Biotec Ltd
EP1239856A1 (en) 1999-12-22 2002-09-18 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
EP1272181A2 (en) 2000-04-13 2003-01-08 Synthon B.V. Modified release formulations containing a hypnotic agent
IN190963B (es) * 2000-06-20 2003-09-06 Ajanta Pharma Ltd
EP1545468A4 (en) 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
EP1462098B1 (en) * 2003-03-03 2007-07-04 SPRL Franpharma Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone

Also Published As

Publication number Publication date
TNSN08018A1 (en) 2009-07-14
BRPI0613547A2 (pt) 2011-01-18
AR055090A1 (es) 2007-08-08
KR20080032209A (ko) 2008-04-14
RS20080020A (sr) 2009-05-06
US20100204333A1 (en) 2010-08-12
UA89684C2 (ru) 2010-02-25
EP1906933A2 (en) 2008-04-09
ZA200801592B (en) 2009-10-28
CA2614850A1 (en) 2007-01-25
AU2006271150A1 (en) 2007-01-25
CN101227893A (zh) 2008-07-23
EA200800370A1 (ru) 2008-06-30
WO2007010559A3 (en) 2007-09-20
JP2009501785A (ja) 2009-01-22
WO2007010559A2 (en) 2007-01-25
MX2008000967A (es) 2008-03-26
NO20080697L (no) 2008-04-18
DE202006020331U1 (de) 2008-09-18
DK200900115U1 (en) 2009-10-23

Similar Documents

Publication Publication Date Title
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CR20110684A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
BRPI0821255A2 (pt) Derivados de espiroindolinona
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
MX2012011504A (es) Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
CR20170159A (es) Nuevos compuestos tricíclicos
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CR20120130A (es) Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
MX2009013332A (es) Inhibidores de ire-1 alfa.
HN2009000968A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp
DOP2006000170A (es) Nuevos derivados de espirocromanona
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
CR10573A (es) Derivados del pirazol como inhibidores del citocromo p450
CL2007002381A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
PA8667201A1 (es) Nuevos compuestos farmaceuticos
UY32299A (es) Composiciones farmacéuticas líquidas
SV2005001805A (es) 3-aminopirrolidinas como inhibidores de la captacion de monoamina ref. x-15735
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
DOP2011000053A (es) Agentes antifungicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)